amr industry alliance
The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.
read moreWe drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:
shared goals
We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.
progress report
In 2018, the Alliance published its first progress report that provides unique insights into the practical steps its members are taking to respond to AMR. The findings of the report illustrate both the challenges the healthcare sector faces in tackling AMR and how the industry is essential to winning this battle.
in action
Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.
latest news
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all st...
Read more
Multiple Alliance Members Co-sign the Canadian Declaration on Antimicrobial Resistance
The International Council of Biotechnology Associations (ICBA) supports the Canadian Declaration on Combatting Antimicrobial Resistance, signed by biopharmaceutical and diagnostic companies in Canada...
Read more
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come
The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches its first progress report today. The re...
Read moreamr in numbers
AMR Impact
Life-sciences at the forefront of the battle against AMR
Development of National Action Plans
R&D
Biotechs
Diagnostics
from the blog
Drugs companies are rising to the challenges of research into superbugs
This letter was first published on the Financial Times on 4th July 2018, in response to the article titled "Pharma sector failing to tackle superbugs, says O’Neill" (26th June 2018) I respectfully disagree with Jim O’Neill’s comments on pharmaceutical companies’ inaction on combating ant...
Read more view all
